January 12, 2016. Dear Amy Yang:



Similar documents
GE Healthcare MAR

February 5, Dear Kristin Pabst,

May 7, Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413

October 28, Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

November 20, Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

February 22, Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

University of Texas Medical School at Houston. April 14, 2015

DICOM Grid, Inc. January 25, Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

Q(K SVJM~jPagelIof 3

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589

April 7, Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

June 9, Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401

May 5, Dear Mr. Courtney:

March 31, Etiometry, Inc. Richard Galgon Independent Consulting Associate Quintiles 5846 Cobblestone Lane Waunakee, Wisconsin 53597

August 12, Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

0 EC V-,) 133 Lj9a

July 24, Dear Ms. Rhodes:

August 21, TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

AW Server 510 (k) Summary of Safety and Effectiveness

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

(k)Suminary k

March 3, Dear Ms. Alice Gong,

JUN 2 6 butt. EkoSonicTM Endovascular System with Rapid Pulse Modulation

Datrix, Inc NOV Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

Simpler Implant Solutions Inc Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com Telephone Fax K080115

March 20, Dear Mr. Chen:

kok1 UQ 510(k)J Device {Applicant 510(k) Summary (per 21 CFR (c)) OCT Applicant

September 25, Dear Ms. McCoy:

510(K) SUMMARY [as required by section (c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

510(k) Summary GlobalMedia Group, LIC. MAY CONiM

SECTION 5 BARDEX TEMPERATURE-SENSING FOLEY CATHETER 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

Lewis Ward L.W. Ward and Associates, Inc Kirkwood Court Boulder, CO

Ni Hau Industrial Co., Ltd. Ms. Lyn Chiu Sales Manager No. 15, Alley 125, Lane 318, Section 2, An Ho Road Tainan City, Taiwan 70967

510(k) Summary. Dentsply Implants. April 30, 2013

,11 DSA Cable, transducer and VS3, VS4 electrode, patient connector

July 21, Dentca, Inc. c/o Mr. Claude Berthoin Denterprise International, Inc. 110 East Granada Blvd, Suite 207 Ormond Beach, Florida 32176

SUMMARY OF SAFETY AND EFFECTIVENESS for Powered Muscle Stimulator

EM GR.OUF DIPLOMAT. OT39?1 Company Name: (K)SUMMARY Oc. Submission Correspondent. Emergo Group, Inc. Company Address:

Building 6, Suite 300 RyeBrook, NY C-ontact-N~ame: --- William H-. Schofield Director of TeleHealth Operations. Signal,_Radiofrequency

Section 5-510(k) Summary. This document is provided in the following pages. DEC

510(K) SUMMARY. 510(k) Number KOS'00-r

November 17, Nanova Biomaterials, Inc. Mr. Andrew Ritts Senior Research Scientist 3806 Mojave Ct Columbia, Missouri, 65202

BMR ~131o-lvleccai Kesearcn Ltd.

Dear Ms. Lucas: This letter corrects our substantially equivalent letter of February 18, 2016.

D I Z1. 510(k) Summary. Section 5. Siemens Medical Solutions USA, Inc. Oncology Care Systems. Date Prepared: September 09,

Ultimate Concepts Inc.

510(k) Summary. Atlanti STM Abutment and AtlantisTM Crown Abutment in Zirconia for Dentsply Ankylos Implant

sbchoi~kku.edu jeremy~sooil.com DANA Diabecare IlS Insulin Infusion pump Infusion pump Class II

May 22, Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216

KIZ 2,33-3 p8 ~ 510(k) Summary. As required by 21 CFR (c) 510(k) Premarket Notification Submission AFrame Digital MobileCare Monitor.

510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc.

MAR (k) SUMMARY OF SAFETY AND EFFECTIVENESS (21CFR ) 1. DATE PREPARED: 4/21/2008

AgaMatrucx. NV2 21 Salem, NH oz (k) Sumnmary

RAMSOFT BUG ,-. I"-, --I 2 N Tel: (416) Fax: (416) sales@ramsoftbiz (k) Summary

L~l t l V~! MAY ?

MViAKIO. V.A hn2 ATTACHMENT I 610(K) SUMMARY. Submitter:

October 29, Dear Ms. Hartnett:

Dental Morelli Ltda.

51O(K) SUMMARY: Therapy family of devices.

510(k) SUMMARY JUL Otoharmonics 0 Levo 9 System

510(k) Summary of Safety and Effectiveness JUN Hip prosthesis

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL Manager of Instrumentation Products

DEC The three components of the Axxent Electronic Brachytherapy System include the Controller, Balloon Applicators-BR and X-ray Source.

March 23, Vision Quest Industries, Inc. Mr. Mohammed Ouerghi Director of QA/RA 1390 Decision Street, Suite A Vista, CA 92081

MAY SECTION VIII. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

May 20, Ivoclar Vivadent Ag Ms. Donna Hartnett Director Regulatory Affairs Ivoclar Vivadent, Inc. 175 Pineview Drive Amherst, New York 14228

510(k) Summary (c)

510(k) SUMMARY APR Date: 15 th December 2008

510(K) Summary K102148

foq8 510(k) Summary fo r PAIRIETEX ~ COMPOSITE Mesh

Manufacturing Technology, Inc.

Fresenius Medical Care

OCT 18 20U5Ibko. a. Submitter Name: Cosmetic Dental Materials Inc. (CDM Inc.) b. Submitter Address: 812 Water St. NE Albany OR 97321

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007

MAY Attachment (k) Summary 21 CER

ItP. Section I. 510(k) Summary of Safety and Effectiveness. Applicant:

DEC V,(9/azO (c 0 j

510(k) SUMMARY. OPTION-vyM Urinary Catheter

JN (k) Summary Device Identification: Device Description:

Section (K) Summary. Kimberly-Clark Corporation Winchester Road Neenah, WI 54956

I C 5 5l v ri 510(K) SUMMARY. Prowess Panther

Summary of Safety and Effectiveness

ELASTO-GEL MANIJKAH"O"NEY JUUjj 2. fudbthsarltvl of the wound fluid, while re~leas'ing

Food and Drug Administration 5 10(k) Notijfication - Partial & Total Ossicular Replacement Prostheses AUG I June 30, 2006

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

May 13, FUJIFILM Sonosite, Inc. Responsible Third Party Official Regulatory Technology Services LLC th Street, NW BUFFALO MN 55313

510(k) Summary Special Premarket Notification 510(k) Section 6

510(k) Summary. (508) X222 Disposable Insulin Delivery Device

Transcription:

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy Yang Regulatory Affairs Program Manager 9900 West Innovation Drive Wauwatosa, Wisconsin 53226 Re: K152993 Trade/Device Name: Muse Cardiology Information System Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: December 10, 2015 Received: December 14, 2015 Dear Amy Yang: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 - Amy Yang Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/medicaldevices/resourcesforyou/industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/medicaldevices/safety/reportaproblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/medicaldevices/resourcesforyou/industry/default.htm. Sincerely yy yours, Enclosure for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below. 510(k) Number (if known) K152993 Device Name MUSE Cardiology Information System Indications for Use (Describe) The MUSE Cardiology Information System is intended to store, access and manage cardiovascular information on adult and pediatric patients. The information consists of measurements, text, and digitized waveforms. The MUSE Cardiology Information System provides the ability to review and edit electrocardiographic procedures on screen, through the use of reviewing, measuring, and editing tools including ECG serial comparison and interpretive 12-lead analysis. The MUSE Cardiology Information System is intended to be used under the direct supervision of a licensed healthcare practitioner, by trained operators in a hospital or facility providing patient care. The MUSE Cardiology Information System is not intended for real-time patient monitoring. The MUSE Cardiology Information System is not intended for pediatric serial comparison. Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number. FORM FDA 3881 (8/14) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF

510(k) Summary In accordance with 21 CFR 807.92 the following summary of information is provided: Date: 09 October 2015 Submitter: Primary Contact Person: Secondary Contact Person: Device Trade Name: Common/Usual Name: Classification Names: Regulatory Class: Product Code: Predicate Device(s): 9900 Innovation Drive Wauwatosa, WI 53226 Amy Yang Regulatory Affairs Program Manager Phone: (414)721-3807 Fax: (414) 721-3863 Doug Kentz Regulatory Affairs Director Phone: (414)581-8987 Fax: (414)362-2585 MUSE Cardiology Information System ECG Analysis Computer Programmable Diagnostic Computer (21 CFR 870.1425) II DQK MUSE Cardiology Information System K130155 12SL ECG Analysis Program K141963 No reference devices were used in this submission Page 1 of 4

Device Description: Intended Use: The MUSE Cardiology Information System is a network based cardiology information management system that manages adult and pediatric diagnostic cardiology data by providing centralized storage and ready access to a wide range of data types and reports from GE and non-ge data acquisition devices. The MUSE Cardiology Information System provides the ability to: Review and edit stored data consisting of measurements, text, and digitized waveforms on screen, through the use of reviewing, measuring, and editing tools including ECG serial comparison and interpretive 12-lead analysis. Generate formatted management reports, ad-hoc database search reports and clinical patient reports on selected stored data. Translates and transfers patient demographic and administrative data from EMR/HIS systems to clinical acquisition devices and translates and transfers tests results from clinical acquisition devices to EMR/HIS systems. Configurable workflow capabilities for managing administrative and clinical tasks in the diagnostic cardiology department, including order/patient demographic management, clinical test review/edit, clinical report distribution, and billing. The MUSE Cardiology Information System is intended to store, access and manage cardiovascular information on adult and pediatric patients. The information consists of measurements, text, and digitized waveforms. The MUSE Cardiology Information System provides the ability to review and edit electrocardiographic procedures on screen, through the use of reviewing, measuring, and editing tools including ECG serial comparison and interpretive 12- lead analysis. The MUSE Cardiology Information System is intended to be used under the direct supervision of a licensed healthcare practitioner, by trained operators in a hospital or facility providing patient care. The MUSE Cardiology Information System is not intended for real time monitoring. The MUSE Cardiology Information System is not intended for pediatric serial comparison. Page 2 of 4

Comparison of Technological Characteristics with the predicate device: At a high level, the subject and predicate devices are based on the following same technological elements: Incorporated12SL ECG Analysis Program provides computerized measurements and interpretive diagnostic statements that assist the physician interpreting the ECG. Review and edit stored data consisting of measurements, text, and digitized waveforms on screen, through the use of reviewing, measuring, and editing tools including ECG serial comparison and interpretive 12-lead analysis. Generate formatted management reports, ad-hoc database search reports and clinical patient reports on selected stored data. Translates and transfers patient demographic and administrative data from EMR/HIS systems to clinical acquisition devices and translates and transfers tests results from clinical acquisition devices to EMR/HIS systems. Configurable workflow capabilities for managing administrative and clinical tasks in the diagnostic cardiology department, including order/patient demographic management, clinical test review/edit, clinical report distribution, and billing. The following technological differences exist between the subject and predicate devices: The DICOM communication services provide workflow functionality for managing ECG Test orders and results as an alternative to HL7. edoc connection feature provide the ability for the user to create custom test types and import test data using industry standard formats. LDAP/AD authentication and authorization provide user the ability to log into the MUSE system using the customer s AD infrastructure. Page 3 of 4

Technology: Determination of Substantial Equivalence: The proposed MUSE Cardiology Information System is a software device that runs on IT hardware employing the same functional scientific technology as the predicate device MUSE Cardiovascular Information System (K130155). Summary of Non-Clinical Tests: The MUSE Cardiology Information System complies with voluntary standards: IEC 62304:2006 Medical device software Software life-cycle processes IEC 62366:2007 Medical devices Application of usability engineering to medical devices. EN ISO 14971:2012 Medical devices Application of risk management to medical devices The following quality assurance measures are applied to the development of the system: Risk Analysis Requirements Reviews Design Reviews Code Inspection Testing on unit level (Module verification) Integration testing (System verification) Performance testing (Verification) Safety testing (Verification) Simulated use testing (Validation) Summary of Clinical Tests: The subject of this premarket submission, MUSE Cardiology Information System, did not require clinical studies to support substantial equivalence. Conclusion: considers the MUSE Cardiology Information System to be as safe, as effective, and performance is substantially equivalent to the predicate device. Page 4 of 4